Ebola is out front, but scientists are catching up
Share
The Ebola outbreak in central Africa is getting worse. The virus is turning up beyond the borders of the Democratic Republic of Congo (DRC), with cases reported in Kenya and Nigeria.
The numbers are alarming. By 24 October, the DRC had recorded 9,964 confirmed cases and 4,851 deaths, making this the country’s biggest and deadliest Ebola outbreak on record.
It was declared on 15 May and involves the Bundibugyo virus, a different type of Ebola virus from the one behind the devastating West African epidemic of 2014–2016.
And there's little sign it’s slowing down. The World Health Organization (WHO) says the virus is spreading rapidly and reaching new areas. Eight provinces in the DRC have now been affected: Ituri, North Kivu, South Kivu, Tshopo, Haut-Uélé, Bas-Uélé, Sud-Ubangi and Nord-Ubangi.
Neighbouring countries are also on high alert.
In Kenya, nine people had tested positive by 25 October, and two had died. All nine cases have been traced back to the first patient, who travelled from the DRC through Uganda.
Uganda managed to bring its earlier outbreak under control in August, but authorities aren’t taking any chances. On 25 October, they tightened border controls, including a new rule requiring Ugandan citizens returning home to quarantine for 21 days – at their own expense.
Nigeria confirmed its first case on 20 October. The patient, a woman who had travelled from Uganda, was reported to be in a stable condition and was flown to Switzerland on 26 October. Nigerian health officials are monitoring 52 people who may have been exposed to the virus, while investigators work to establish how she became infected.
Why is Ebola proving so difficult to contain?
There isn’t one simple answer. Several challenges are making an already dangerous situation even harder to manage. For starters, there’s currently no approved vaccine or treatment specifically designed for Bundibugyo virus disease.
That means health workers must rely on supportive medical care.
But one of the biggest problems is that too many people are dying before they can get medical help.
Of the 482 additional deaths recorded in the WHO’s latest reporting period, 307 happened outside treatment centres, in local communities.
That’s a worrying sign that people aren’t being diagnosed or reaching treatment facilities early enough.
Is there any good news?
Yes, but the outbreak is far from under control.
One promising development came on 23 October, when researchers in Bunia, in the DRC, began enrolling volunteers in the TUMAINI vaccine trial.
The Phase 2/3 trial will test potential vaccines against the Bundibugyo virus. It's an important step, but it’s still a research trial, not a vaccine that’s ready to roll out.
There’s also been progress in getting more people into treatment. By 23 October, more than 2,000 treatment beds were available, with health authorities working towards a target of 3,000.
Around 2,600 people in the DRC had also survived the disease.
And there’s another encouraging sign: health workers have recently seen a drop in the number of people dying outside treatment centres. That suggests more patients may be getting medical attention sooner.
Why testing matters – and where Celtic comes in
Speed is critical when it comes to stopping Ebola. And one of the most important tools health workers have is the ability to identify the virus quickly and accurately.
It’s especially important in the current outbreak because not all Ebola tests are designed to detect the Bundibugyo virus. A test that works for another type of Ebola virus could miss this one.
And that’s where molecular diagnostic testing comes in. The main test used is RT-PCR, short for reverse-transcription polymerase chain reaction.
Celtic Molecular Diagnostics supplies the Altona Diagnostics RealStar® Filovirus Screen RT-PCR Kit 1.0. In August 2026, the WHO added the kit to its Emergency Use Listing (EUL) specifically for detecting the Bundibugyo virus, giving it important international recognition for outbreak testing.
It detects Ebola and Marburg virus RNA in human EDTA plasma and works with many different lab machines, giving labs with existing molecular testing setups more options. Its global importance is also shown by the European Commission’s decision to buy €2.1-million worth of Altona’s open-platform Ebola PCR tests to donate to the WHO.
The idea behind RT-PCR testing is fairly straightforward. The test looks for the virus’s genetic material, usually in a blood sample. In other words, rather than relying on symptoms alone, it checks for evidence that the virus itself is present.
It’s recommended to confirm an Ebola infection and identify exactly which Ebola virus is responsible. It’s important – in the early stages, Ebola can look a lot like other illnesses, including malaria. Fever, headaches, muscle pain and general weakness aren’t exactly unusual symptoms in many parts of Africa.
Testing provides the answers needed to make the right decisions about care and treatment. In an outbreak like this, a quick, reliable diagnosis can have a huge impact.